{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abraxane%C2%AE&page=6", "query": { "intervention": "Abraxane®", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 249, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abraxane%C2%AE&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abraxane%C2%AE&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T03:52:30.292Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01207102", "title": "Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Abraxane", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2011-08", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2014-12-15", "last_synced_at": "2026-10-06T03:52:30.292Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01207102" }, { "nct_id": "NCT00398086", "title": "Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Albumin-bound paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2006-11-01", "completion_date": "2010-12-01", "has_results": true, "last_update_posted_date": "2019-11-22", "last_synced_at": "2026-10-06T03:52:30.292Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Baltimore, Maryland + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00398086" }, { "nct_id": "NCT00652119", "title": "Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Avastin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 46, "start_date": "2008-02", "completion_date": "2021-08", "has_results": false, "last_update_posted_date": "2020-08-19", "last_synced_at": "2026-10-06T03:52:30.292Z", "location_count": 5, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00652119" }, { "nct_id": "NCT07216703", "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Rescue Medications", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1023, "start_date": "2026-01-19", "completion_date": "2031-10-29", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-06T03:52:30.292Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Irvine, California • Orange, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216703" }, { "nct_id": "NCT01929941", "title": "An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Hodgkin's Lymphoma", "NHL (Non-Hodgkin Lymphoma)", "Pancreatic Cancer", "Breast Cancer", "UC (Ureter and Urethera)", "Advanced Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "INCB047986", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2013-09", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-10-06T03:52:30.292Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Nashville, Tennessee • Dallas, Texas", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01929941" }, { "nct_id": "NCT01256268", "title": "Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "Ridaforolimus", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2011-06-13", "completion_date": "2017-08-03", "has_results": false, "last_update_posted_date": "2017-08-30", "last_synced_at": "2026-10-06T03:52:30.292Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01256268" }, { "nct_id": "NCT03703063", "title": "Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab paclitaxel", "type": "DRUG" }, { "name": "Onivyde", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fu", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Benaroya Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-09-17", "completion_date": "2022-09-17", "has_results": false, "last_update_posted_date": "2021-01-27", "last_synced_at": "2026-10-06T03:52:30.292Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03703063" }, { "nct_id": "NCT00110084", "title": "ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2005-08", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2011-06-02", "last_synced_at": "2026-10-06T03:52:30.292Z", "location_count": 201, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 129 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110084" }, { "nct_id": "NCT02270814", "title": "Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma", "Cancer of the Head and Neck" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2015-02-02", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-06T03:52:30.292Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Jackson, Mississippi • St Louis, Missouri + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Fargo", "state": "North Dakota" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02270814" }, { "nct_id": "NCT07772882", "title": "Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Platinum Resistant Ovarian Cancer", "Fallopian Tube Cancers", "Peritoneal Carcinoma" ], "interventions": [ { "name": "Cohort A1", "type": "DRUG" }, { "name": "Cohort A2", "type": "DRUG" }, { "name": "Cohort A3", "type": "DRUG" }, { "name": "A3 Expansion", "type": "DRUG" }, { "name": "Cohort B1", "type": "DRUG" }, { "name": "Cohort B2", "type": "DRUG" }, { "name": "Cohort B3", "type": "DRUG" }, { "name": "B3 Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rebecca Arend", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "FEMALE", "summary": "18 Years to 89 Years · Female only" }, "enrollment_count": 24, "start_date": "2026-09", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-06T03:52:30.292Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07772882" } ] }